



**Biotech Sepal Pharma Announces Participation to Rodman & Renshaw 5th
Annual Global Healthcare Conference, May 19-20 2008
in Monte Carlo, Monaco, at the Meridien Beach Plaza Hotel**

Paris, France, and Nes Ziona, Israel, Wednesday May 14th – The privately-held biotechnology company Sepal Pharma (www.sepalpharma.com), specialized in the development of novel anti-cancer drug-candidates derived from the jasmonate family of compounds, announces its participation to Rodman & Renshaw 5th annual Global Healthcare conference in Monte Carlo, Monaco, from May 19th to May 20th.

The Rodman & Renshaw Healthcare conference in Monte Carlo offers selected emerging life sciences companies a unique platform to attract the attention of industry-leading institutional investors, venture capitalists, sophisticated private investors, and business development & partnering executives. This year, a selection of 175 emerging growth biotechnology companies will be presenting.

Sepal Pharma will be represented by its recently appointed Chief Executive Officer, Frédéric Revah, PhD., who will be presenting the company on May 19th at 8:40 am in Atlantique Salon – Eastern (2nd Floor). The webcast of the presentation will be available online, as soon as May 19th, on <http://www.com/webcast/rrshq13/sepal>.

About Sepal Pharma

Founded in 2003, Sepal Pharma is a biotechnology company developing novel anti-cancer drug candidates, derived from the jasmonate family of compounds. These New Chemical Entities (NCEs) are selectively active against cancer cells with limited side-effects and can be used in broad therapeutic cancer indications (“pan-cancer”).

Sepal Pharma’s breakthrough technology is based on Professor Eliezer Flescher’s (the Tel-Aviv University) research on the anticancer effect of jasmonates. Sepal’s lead compound has undergone preliminary Phase I trial in CLL patients, and its novel NCEs are at preclinical stage. Sepal holds a strong and unique intellectual property portfolio on the jasmonates in the oncology field. It ensures the company scientific leadership and competitive advantage over competitors.

The company collaborates with prestigious partners from both the academic and industrial worlds, including: Ariana Pharmaceuticals, Tel Aviv University, Kaplan Medical Center, Pasteur Institute, INSERM, Hopital Pitié Salpêtrière, etc..Sepal Pharma counts 10 employees and is headquartered in Paris, France, with its laboratories in Nes Ziona, Israel. You can visit our web site at: www.sepalpharma.com

Contacts

Sepal Pharma

Frédéric Revah, PhD.

CEO

frederic.revah@sepalpharma.com

ALIZE RP

Caroline Carmagnol

+ 33 6 64 18 99 59

caroline@alizerp.com